Protagonist Therapeutics (PTGX) Rating Increased to Hold at BidaskClub
BidaskClub upgraded shares of Protagonist Therapeutics (NASDAQ:PTGX) from a sell rating to a hold rating in a research report report published on Saturday.
A number of other brokerages also recently commented on PTGX. Stifel Nicolaus initiated coverage on Protagonist Therapeutics in a research report on Monday, January 29th. They set a buy rating and a $32.00 price objective for the company. Zacks Investment Research downgraded Protagonist Therapeutics from a strong-buy rating to a hold rating in a research report on Thursday, January 4th. Finally, BMO Capital Markets boosted their price objective on Protagonist Therapeutics from $40.00 to $43.00 and gave the stock an outperform rating in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. Protagonist Therapeutics currently has an average rating of Hold and an average price target of $32.50.
Shares of Protagonist Therapeutics (PTGX) traded up $3.45 during trading on Friday, hitting $20.86. The stock had a trading volume of 266,938 shares, compared to its average volume of 91,745. Protagonist Therapeutics has a 1-year low of $8.00 and a 1-year high of $23.75. The firm has a market capitalization of $427.21, a P/E ratio of -7.75 and a beta of 1.62.
A number of hedge funds have recently bought and sold shares of PTGX. Bank of Montreal Can lifted its stake in Protagonist Therapeutics by 1,086.0% during the fourth quarter. Bank of Montreal Can now owns 5,930 shares of the company’s stock worth $123,000 after purchasing an additional 5,430 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Protagonist Therapeutics by 60.8% during the third quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock worth $169,000 after purchasing an additional 3,617 shares during the last quarter. Teachers Advisors LLC lifted its stake in Protagonist Therapeutics by 71.4% during the second quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock worth $183,000 after purchasing an additional 6,757 shares during the last quarter. California State Teachers Retirement System lifted its stake in Protagonist Therapeutics by 8.5% during the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock worth $188,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in Protagonist Therapeutics during the fourth quarter worth approximately $197,000. Hedge funds and other institutional investors own 47.54% of the company’s stock.
WARNING: This article was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/03/04/protagonist-therapeutics-ptgx-rating-increased-to-hold-at-bidaskclub.html.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.